Related Experiment Videos
[Platelet aggregation and P-selectin concentration in patients on peritoneal dialysis treated with erythropoietin]
J Małyszko1, E Suchowierska, K Pawlak
1Klinika Nefrologii i Chorób Wewnetrznych AM w Białymstoku.
In chronic renal failure disturbances of hemostasis are predominantly due to the defective platelet function and platelet/vessel wall interactions. Erythropoietin, used for treatment of renal anemia, affect hemostasis in dialyzed patients. The aim of the work was to assess platelet aggregation and P-selectin concentration in patients on continuous ambulatory peritoneal dialysis (CAPD) during erythropoietin therapy. The studied were performed on 12 CAPD patients, administered with subcutaneous erythropoietin in a dose of 2000 U three times a week for 3 months. Hemoglobin, hematocrit and erythrocyte count increased significantly after 1 month of the treatment. Platelet aggregation in platelet-rich plasma induced by collagen, ristocetin and serotonin increased significantly after 3 months of erythropoietin therapy when compared to the baseline values. Whole blood platelet aggregation and P-selectin concentration did not change significantly during 3 months of erythropoietin therapy. Erythropoietin treatment in CAPD patients did not affect significantly platelet aggregation and activation.
In chronic renal failure disturbances of hemostasis are predominantly due to the defective platelet function and platelet/vessel wall interactions. Erythropoietin, used for treatment of renal anemia, affect hemostasis in dialyzed patients. The aim of the work was to assess platelet aggregation and P-selectin concentration in patients on continuous ambulatory peritoneal dialysis (CAPD) during erythropoietin therapy. The studied were performed on 12 CAPD patients, administered with subcutaneous erythropoietin in a dose of 2000 U three times a week for 3 months. Hemoglobin, hematocrit and erythrocyte count increased significantly after 1 month of the treatment. Platelet aggregation in platelet-rich plasma induced by collagen, ristocetin and serotonin increased significantly after 3 months of erythropoietin therapy when compared to the baseline values. Whole blood platelet aggregation and P-selectin concentration did not change significantly during 3 months of erythropoietin therapy. Erythropoietin treatment in CAPD patients did not affect significantly platelet aggregation and activation.